These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 8577927)

  • 1. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides.
    Hupe-Sodmann K; McGregor GP; Bridenbaugh R; Göke R; Göke B; Thole H; Zimmermann B; Voigt K
    Regul Pept; 1995 Aug; 58(3):149-56. PubMed ID: 8577927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endoproteolysis of glucagon-like peptide (GLP)-1 (7-36) amide by ectopeptidases in RINm5F cells.
    Hupe-Sodmann K; Göke R; Göke B; Thole HH; Zimmermann B; Voigt K; McGregor GP
    Peptides; 1997; 18(5):625-32. PubMed ID: 9213354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum.
    Mentlein R; Gallwitz B; Schmidt WE
    Eur J Biochem; 1993 Jun; 214(3):829-35. PubMed ID: 8100523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endoproteolysis by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, exendins-3 and -4.
    Thum A; Hupe-Sodmann K; Göke R; Voigt K; Göke B; McGregor GP
    Exp Clin Endocrinol Diabetes; 2002 May; 110(3):113-8. PubMed ID: 12012270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulation and degradation of GIP and GLP-1.
    Deacon CF
    Horm Metab Res; 2004; 36(11-12):761-5. PubMed ID: 15655705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular cloning, functional expression, and signal transduction of the GIP-receptor cloned from a human insulinoma.
    Volz A; Göke R; Lankat-Buttgereit B; Fehmann HC; Bode HP; Göke B
    FEBS Lett; 1995 Oct; 373(1):23-9. PubMed ID: 7589426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.
    Gault VA; O'Harte FP; Harriott P; Mooney MH; Green BD; Flatt PR
    Diabetologia; 2003 Feb; 46(2):222-30. PubMed ID: 12627321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Priming effect of glucagon-like peptide-1 (7-36) amide, glucose-dependent insulinotropic polypeptide and cholecystokinin-8 at the isolated perfused rat pancreas.
    Fehmann HC; Göke R; Göke B; Bächle R; Wagner B; Arnold R
    Biochim Biophys Acta; 1991 Feb; 1091(3):356-63. PubMed ID: 1705823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide.
    Kolligs F; Fehmann HC; Göke R; Göke B
    Diabetes; 1995 Jan; 44(1):16-9. PubMed ID: 7813808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A synthetic glucagon-like peptide-1 analog with improved plasma stability.
    Ritzel U; Leonhardt U; Ottleben M; Rühmann A; Eckart K; Spiess J; Ramadori G
    J Endocrinol; 1998 Oct; 159(1):93-102. PubMed ID: 9795346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
    Nauck MA; Bartels E; Orskov C; Ebert R; Creutzfeldt W
    J Clin Endocrinol Metab; 1993 Apr; 76(4):912-7. PubMed ID: 8473405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma and intestinal concentrations of GIP and GLP-1 (7-36) amide during suckling and after weaning in pigs.
    Knapper JM; Morgan LM; Fletcher JM; Marks V
    Horm Metab Res; 1995 Nov; 27(11):485-90. PubMed ID: 8770623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of effect of synthetic human gastric inhibitory polypeptide and glucagon-like peptide 1 [7-36 amide] infused at near-physiological concentrations on pentagastrin-stimulated gastric acid secretion in normal human subjects.
    Nauck MA; Bartels E; Orskov C; Ebert R; Creutzfeldt W
    Digestion; 1992; 52(3-4):214-21. PubMed ID: 1459356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the entero-pancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1(7-36) amide, on fatty acid synthesis in explants of rat adipose tissue.
    Oben J; Morgan L; Fletcher J; Marks V
    J Endocrinol; 1991 Aug; 130(2):267-72. PubMed ID: 1919397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GLP-1/GIP chimeric peptides define the structural requirements for specific ligand-receptor interaction of GLP-1.
    Gallwitz B; Witt M; Morys-Wortmann C; Fölsch UR; Schmidt WE
    Regul Pept; 1996 May; 63(1):17-22. PubMed ID: 8795084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects.
    Meier JJ; Nauck MA; Kranz D; Holst JJ; Deacon CF; Gaeckler D; Schmidt WE; Gallwitz B
    Diabetes; 2004 Mar; 53(3):654-62. PubMed ID: 14988249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastric inhibitory polypeptide analogues: do they have a therapeutic role in diabetes mellitus similar to that of glucagon-like Peptide-1?
    Holst JJ
    BioDrugs; 2002; 16(3):175-81. PubMed ID: 12102645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Release of glucagon-like peptide 1 (GLP-1 [7-36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections.
    Nauck MA; Siemsglüss J; Orskov C; Holst JJ
    Z Gastroenterol; 1996 Mar; 34(3):159-66. PubMed ID: 8650968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proadrenomedullin N-terminal 20 peptide is rapidly cleaved by neutral endopeptidase.
    Nagatomo Y; Kitamura K; Kangawa K; Fujimoto Y; Eto T
    Biochem Biophys Res Commun; 1996 Jun; 223(3):539-43. PubMed ID: 8687431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39).
    Green BD; Mooney MH; Gault VA; Irwin N; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
    Metabolism; 2004 Feb; 53(2):252-9. PubMed ID: 14767880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.